Drugs / B38-CAP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04382950 | Jul → Aug 2021 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 1 | NCT04375046 | Jul → Aug 2021 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B38-CAP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04375046 ↗ |
| Known as | rbACE2 | “Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)” NCT04375046 ↗1“Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)” NCT04382950 ↗ |
| Action | Restore | “it will perform the same role as human ACE2” NCT04375046 ↗ |
| Modality | Protein / enzyme biologic | “B38-CAP is an ACE2-like enzyme derived from bacteria” NCT04375046 ↗ |
| Route | Intravenous | “0.4 mg/kg rbACE2 IV” NCT04375046 ↗ |